产品名称 | 产品编号 | 浓度/详细参数 | CAS号 | 规格/计量单位 | 价格 | 货期 | 品牌 |
---|---|---|---|---|---|---|---|
LASV inhibitor 3.3 | L650254-50mg | ≥99% | 554438-52-7 | 50mg | ¥ 5840.9 | 期货,请咨询 | 阿拉丁 |
LASV inhibitor 3.3 | L650254-25mg | ≥99% | 554438-52-7 | 25mg | ¥ 3650.9 | 期货,请咨询 | 阿拉丁 |
LASV inhibitor 3.3 | L650254-10mg | ≥99% | 554438-52-7 | 10mg | ¥ 1750.9 | 期货,请咨询 | 阿拉丁 |
L-Citrulline-13C | L650230-5mg | ≥98% | 94740-46-2 | 5mg | ¥ 2500.9 | 期货,请咨询 | 阿拉丁 |
L-Citrulline-13C | L650230-10mg | ≥98% | 94740-46-2 | 10mg | ¥ 4000.9 | 期货,请咨询 | 阿拉丁 |
Litronesib | L650229-5mg | ≥97% | 910634-41-2 | 5mg | ¥ 1799.9 | 现货 | 阿拉丁 |
Litronesib | L650229-50mg | ≥97% | 910634-41-2 | 50mg | ¥ 10299.9 | 现货 | 阿拉丁 |
Litronesib | L650229-2mg | ≥97% | 910634-41-2 | 2mg | ¥ 1800.9 | 现货 | 阿拉丁 |
Litronesib | L650229-10mg | ≥97% | 910634-41-2 | 10mg | ¥ 2999.9 | 现货 | 阿拉丁 |
Litronesib | L650229-100mg | ≥97% | 910634-41-2 | 100mg | ¥ 17499.9 | 现货 | 阿拉丁 |
LPA2 antagonist 2 | L650214-5mg | ≥95% | 36840-10-5 | 5mg | ¥ 2699.9 | 现货 | 阿拉丁 |
LPA2 antagonist 2 | L650214-1mg | ≥95% | 36840-10-5 | 1mg | ¥ 899.9 | 现货 | 阿拉丁 |
LPA2 antagonist 2 | L650214-10mg | ≥95% | 36840-10-5 | 10mg | ¥ 4199.9 | 现货 | 阿拉丁 |
L-Glutamine-1-13C | L650203-5mg | ≥98% | 159663-16-8 | 5mg | ¥ 1800.9 | 期货,请咨询 | 阿拉丁 |
L-Glutamine-1-13C | L650203-1mg | ≥98% | 159663-16-8 | 1mg | ¥ 650.9 | 期货,请咨询 | 阿拉丁 |
L-Glutamine-1-13C | L650203-10mg | ≥98% | 159663-16-8 | 10mg | ¥ 2800.9 | 期货,请咨询 | 阿拉丁 |
LUF5771 | L650188-5mg | ≥98% | 1141802-49-4 | 5mg | ¥ 1000.9 | 期货,请咨询 | 阿拉丁 |
LUF5771 | L650188-50mg | ≥98% | 1141802-49-4 | 50mg | ¥ 5500.9 | 期货,请咨询 | 阿拉丁 |
LUF5771 | L650188-25mg | ≥98% | 1141802-49-4 | 25mg | ¥ 3500.9 | 期货,请咨询 | 阿拉丁 |
LUF5771 | L650188-10mg | ≥98% | 1141802-49-4 | 10mg | ¥ 1600.9 | 期货,请咨询 | 阿拉丁 |
LUF5771 | L650188-100mg | ≥98% | 1141802-49-4 | 100mg | ¥ 9500.9 | 期货,请咨询 | 阿拉丁 |
LJ001 | L650182-5mg | ≥98% | 851305-26-5 | 5mg | ¥ 2000.9 | 期货,请咨询 | 阿拉丁 |
LJ001 | L650182-50mg | ≥98% | 851305-26-5 | 50mg | ¥ 10500.9 | 期货,请咨询 | 阿拉丁 |
LJ001 | L650182-25mg | ≥98% | 851305-26-5 | 25mg | ¥ 6500.9 | 期货,请咨询 | 阿拉丁 |